Crossmark

Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial

Crossref DOI link: https://doi.org/10.1186/s12933-017-0529-3

Published Online: 2017-04-04

Published Print: 2017-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Fadini, Gian Paolo http://orcid.org/0000-0002-6510-2097
Bonora, Benedetta Maria

Zatti, Giancarlo

Vitturi, Nicola

Iori, Elisabetta

Marescotti, Maria Cristina

Albiero, Mattia

Avogaro, Angelo
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct02327039 at ClinicalTrials.gov

Documents that mention this clinical trial

Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial
https://doi.org/10.1186/s12933-019-0910-5

Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial
https://doi.org/10.1186/s12933-017-0529-3
Funding

Funding for this research was provided by:

AstraZeneca
License Information

Text and Data Mining valid from 2017-04-04

Version of Record valid from 2017-04-04
More Information

Article History

Received: 25 February 2017

Accepted: 27 March 2017

First Online: 4 April 2017

Document is current

Any future updates will be listed below